Biodexa Advances Serenta Phase 3 Trial in FAP
CARDIFF, U.K., August 19, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced a major recruitment milestone for its Serenta registrational...
Gastrointestinal Cancer
Advertisement
Aravax Wins FDA Fast Track Designation for PVX108
MELBOURNE, Australia & OXFORD, UK, Aug. 3, 2026 Aravax announced that the U.S. Food and Drug Administration (FDA) has...
IMPACT Therapeutics Names IMP3201 First Dual-Payload ADC Candidate
SHANGHAI, China, July 27, 2026 IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the...
Leads Biolabs Completes Opamtistomig Phase II Enrollment in BTC
NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...
Iksuda Therapeutics Secures FDA IND Clearance for IKS04
Newcastle, UK, July 30, 2026 Iksuda Therapeutics has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)...
Advertisements
Oncolytics Biotech Wins FDA Fast Track for Pelareorep
SAN DIEGO, July 20, 2026 Oncolytics Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Multitude Therapeutics Reports Positive AMT-676 Phase I Data
SHANGHAI, China, July 2, 2026 Multitude Therapeutics Co., Ltd. announced encouraging interim Phase I clinical results for its CDH17-directed...
Biodexa Expands Phase 3 Serenta Trial into Canada for FAP
LONDON, United Kingdom, June 29, 2026 Biodexa Pharmaceuticals PLC announced that Health Canada has approved the expansion of its...
Castle TissueCypher Surpasses 100,000 Orders in Barrett’s
FRIENDSWOOD, Texas, June 16, 2026 Castle Biosciences has announced that its TissueCypher® Barrett’s Esophagus Test has surpassed 100,000 clinical...
Oncolytics’ Pelareorep Shows Strong KRAS-Targeted Immune Activation at ASCO 2026
SAN DIEGO, May 22, 2026 Oncolytics Biotech® announced new translational data from its GOBLET and AWARE-1 studies showing that...
Advertisement
